← All trials
NCT03373058
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2018
- Primary completion
- Jul 1, 2021
- Completion date
- Jul 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 214
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Guangzhou Medical UniversityLead sponsor
- Jiao Tong UniversityCollaborator
- Peking UniversityCollaborator
- Fudan UniversityCollaborator
- Central South UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Hebei UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Shandong UniversityCollaborator
- Southern Medical UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
- People's Liberation Army of ChinaCollaborator
- Sun Yat-Sen UniversityStudy director
- Sichuan UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Henan Medical UniversityCollaborator
- Capital Medical UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Guizhou Medical UniversityCollaborator
- Wuhan UniversityCollaborator
- Guangzhou Medical UniversityStudy director
- Chongqing Cancer InstituteCollaborator
- Guangxi Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.